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Arsenic is a metalloid, that is, considered to be a human carcinogen. Millions of individuals worldwide are chronically exposed
through drinking water, with consequences ranging from acute toxicities to development of malignancies, such as skin and lung
cancer. Despite well-known arsenic-related health eﬀects, the molecular mechanisms involved are not fully understood; however,
the arsenic biotransformation process, which includes methylation changes, is thought to play a key role. This paper explores the
relationship of arsenic exposure with cancer development and summarizes current knowledge of the potential mechanisms that
may contribute to the neoplastic processes observed in arsenic exposed human populations.
1.Introduction
Arsenic (As) is a chemical element classiﬁed as a metalloid.
The most common oxidation states in the environment are
+3 (AsIII, also known as arsenite) and +5 (AsV or arsenate),
which exhibit diﬀerent grades of toxicity [1]. Arsenic com-
pounds can be found in organic (when linked with carbon
and hydrogen) and inorganic (when combined with oxygen,
chlorine, and sulfur, among other elements) forms [2].
Long term ingestion of inorganic arsenic has been asso-
ciatedwithseveralhumandiseases.Therearevarioussources
of ingested arsenic, such as food (mainly in ﬁsh and seafood,
algae, and cereals), air (coal-ﬁred power generation and
smelting), and water [3]. Of the various sources of arsenic in
the environment, long-term exposure of arsenic in drinking
water likely poses the greatest threat to human health [4].
Given its daily and widespread consumption, occurrence of
arsenic in drinking water has been increasingly recognized as
a major public health concern in several regions of the world
over the past decades [5–7]. In fact, groundwater used for
drinking contaminated with naturally occurring inorganic
arsenic in Bangladesh represents one of the largest mass
poisoning of a population in history [8]. Worldwide, an
estimated 160 million people live in regions with naturally
elevated levels of arsenic in drinking water, due to the
presence of arsenic-rich geological formations [7].
Arsenic is a natural component of rocks containing cop-
per or lead, which can result in release of arsenic into water
or air in zones of intensive mining activities [6]. Due to
these geological conditions and/or anthropogenic activities,
soil and water supplies in these areas contain high con-
centrations of arsenical compounds [9]. This situation is
compounded in extremely arid zones (such as in Northern
Chile), where water sources are scarce and contaminated
waterservesasadrinkingandirrigationsupply.Thiscanlead
to massive chronic poisoning—called arsenicosis—aﬀecting
localpopulations[10].Arsenic-contaminateddrinkingwater
represents an important public health issue, especially for
developing countries.
Due to its physical characteristics (no odor, no color, and
no ﬂavor), arsenic exposure is often unnoticed, especially
when ingested through drinking water. In this context,
long-term eﬀects are a major health concern in aﬀected
areas. The World Health Organization (WHO) and the
U.S. Environmental Protection Agency have recommended a
threshold of 10μg/L for inorganic arsenic concentration in
drinking water [11, 12]. Unfortunately, millions of people
are exposed to toxic levels and are at increased risk for2 Journal of Toxicology
the adverse health eﬀects of arsenic [6, 13]. Concentrations
exceeding this threshold have been described in Bangladesh,
India, China, Argentina, Mexico, Canada, USA, and Chile,
among other countries [14].
There is a strong body of evidence linking arsenic with a
variety of health problems, from acute toxicities to chronic
diseases which can take years to develop. Arsenic-related
diseases include skin lesions, hypertension, ischemia, some
endemic peripheral vascular disorders (e.g., “black foot
disease”),diabetes,severearteriosclerosis,neuropathies,and,
signiﬁcantly, many types of cancer [15–18]. Cancer-death
risk associated with daily consumption of 1.6 liters of water
with inorganic arsenic (50μg/L) has been estimated to be
21/1,000 [19].
Arsenic has been classiﬁed as a class I human carcinogen
by the International Agency of Research on Cancer (IARC),
meaning that there is suﬃcient evidence of carcinogenicity
to humans. Despite evidence in humans, animal models fail
to replicate these observed eﬀects, hampering elucidation of
the exact mode(s) of action underlying arsenic related car-
cinogenicity [20]. Skin and several types of internal cancers,
including bladder, kidney, liver, prostate, and lung have been
associated with arsenic ingestion [10, 21–25]. Skin cancer is
the most common form of neoplasm associated with arsenic
ingestion, while lung cancer corresponds to the most deadly
[13, 26]. Interestingly, arsenic (speciﬁcally arsenic trioxide or
As2O3)hasbeenusedasachemotherapeuticagentforseveral
types of cancer, with some studies showing high percentage
of response in patients with acute promyelocytic leukemia
(APL) [27, 28]. We will also discuss this issue in further
sections.
2. Common Arsenic-InducedMalignancies
2.1. Skin Cancer. The relationship between arsenic and skin
cancer has been well documented over the past several
decades [29, 30]. The ﬁrst inferences were made through
observations of an increased frequency of skin cancer cases
following treatment with Fowler’s solution (1% potassium
arsenite), formerly used for a variety of skin and hematologi-
caldisorders[31].Bowen’sdisease(intraepithelialcarcinoma
or carcinoma in situ), basal cell carcinoma (BCC)- and
squamous cell carcinoma (SqCC) are the most common
malignancies found in patients with long-term exposure to
arsenic. Merkel cell carcinoma, an uncommon and highly
aggressive cutaneous neoplasm, has been also documented
at a lower frequency [32–35].
Arsenic-related skin SqCC can develop either de novo or
progress from Bowen’s disease, whereas arsenic-related BCC
develops usually in multiple foci and areas of the body
covered from sun exposure, in contrast to cases originating
from other skin carcinogens, such as UV-light [36–38].
Arsenic-related Bowen’s disease can appear 10 years after
arsenic exposure, while other types of skin cancer can have
a latency period of 20 or 30 years [39]. A dose-response
relationship and cell-type speciﬁcity have been described for
arsenic-related skin cancer [40, 41]. Additionally, normal
human epidermal keratinocytes exposed to varying noncy-
totoxic/slightly cytotoxic concentrations of inorganic arsenic
exhibit gene expression changes associated with molecular
pathways relevant to arsenic-related skin carcinogenesis,
such as oxidative stress, increased transcriptional levels of
keratinocyte growth factors, and modulation of MAPK and
NF-κBp a t h w a y s[ 42].
Premalignant skin lesions are relatively early manifesta-
tions of arsenic toxicity and are often considered precursors
to arsenic-induced skin BCC and SqCC tumors [43]. These
lesions include dermal manifestations such hyperpigmenta-
tion (a ﬁnely freckled, “raindrop” pattern of pigmentation
or depigmentation) and hyperkeratosis (skin thickening,
mainly at palms and the feet). These lesions are commonly
foundinchronicallyexposedpopulationsandareconsidered
a diagnostic criterion of arsenicosis [44]. Moreover, some
genetic susceptibilities to these arsenic-related skin lesions
havebeenproposed,sincetheydonotoccurineveryexposed
individual [45]. Hyperkeratosis can appear with shorter
periods of arsenic exposure, and it has been described that
these lesions give rise to the majority of arsenic-induced skin
cancer [46, 47]. Additionally, it has been demonstrated that
a signiﬁcant proportion of fatal cases of skin cancer occurred
in patients with prior signs of arsenicosis, such as keratosis
and hyperpigmentation [31, 48].
In addition to directly aﬀecting the carcinogenic process,
it has been demonstrated that arsenic toxicity can also be
potentiated by other environmental carcinogens. For exam-
ple, arsenic-exposed individuals with a history of smoking
and chronic exposure to environments with high fertilizer
use may be more susceptible to cancer-prone skin lesions
than those without these risk factors, even at the same level
of arsenic exposure [43]. Arsenic can act as a cocarcinogen
with UV light in a synergistic mode of action, leading to
development of hyperkeratosis [49, 50]. Additionally, the
same mode of action was observed between high levels of
arsenic (over 100μg/L) and tobacco smoking with respect to
risk of skin lesions in men [51].
2.2. Lung Cancer. There exists a signiﬁcant dose-response
relationship between arsenic concentration in water and
incidence of lung cancer and other malignancies for both
men and women [52]. The association between lung cancer
and ingested arsenic was discovered following therapeutic
application of this metalloid in psoriasis patients treated
with Fowler’s solution [53–55]. Thereafter, an increased lung
cancer risk following exposure to arsenic in drinking water
was demonstrated by several case-control and cohort-type
studies [20]. Consistent, positive, and statistically signiﬁcant
associations among individuals exposed to high concentra-
tions of arsenic in drinking water and increased risk of
lung cancer have been detected [56, 57]. Based on large
epidemiology studies in 1999, a report from the National
Research Council (NRC, USA) concluded that there was
suﬃcient evidence suggesting that the ingestion of arsenic
in drinking water causes lung cancer, among other types
of malignant neoplasias [58]. After this publication, other
major arsenic and lung cancer epidemiological studies were
published [25, 59]. Due to mounting evidence, the NRCJournal of Toxicology 3
study was reevaluated in 2001, concluding that the carcino-
genic eﬀects of arsenic in humans are signiﬁcant, and that
lung (and bladder) cancer should continue to be the focus of
arsenic risk assessment for regulatory decision making [60].
Interestingly, the increase risk of lung cancer associated
with arsenic seems to be cancer subtype speciﬁc. For ex-
ample, where SqCC incidence had decreased worldwide and
overwhelminglyassociatedwithcigarettesmoking;inNorth-
ern Chile, a high proportion of SqCC frequently occurs in
never smokers who have been chronically exposed to arsenic
[25, 61].
As mentioned, Bangladesh represents the largest mass
poisoningofapopulationinhistory,asgroundwaterusedfor
drinking is contaminated with naturally occurring inorganic
arsenic [8]. In rural areas in Bangladesh, arsenic contami-
nation in drinking water from tube wells is associated with
lungcancerinmales,withlungSqCCbeingthepredominant
histological subtype in areas with arsenic concentrations
above 100μg/L [62]. In these areas, the lifetime mortality
risks of lung cancer are 159.1/100 000 for males and 23.1 for
females (per 100 000 population) [63].
Blackfoot disease (BFD) is an endemic, peripheral arte-
rial disease characterized by severe systemic arteriosclerosis
and spontaneous gangrene resulting in amputation, com-
mon to individuals exposed to arsenic in Southwestern
Taiwan [18]. In zones aﬀected by BFD, increased incidence
and subsequent mortality rates for lung cancer have been
demonstrated, especially among those who used arsenic-
contaminated well water for ≥40 years [64]. Smokers in
this area have a 4.1-fold higher relative risk for lung cancer,
suggesting apossible synergistic relationship between arsenic
and tobacco exposures in terms of lung tumorigenesis [65].
Also, short-term exposure (5 years) of arsenic-contaminated
drinking water (≥0.05μg/L) can also result in elevated lung
cancer risk [66].
The Andean zone in South America is another area
where the relationship between chronic arsenic exposure
and lung cancer has been demonstrated. A dose-response
relationship between arsenic in drinking water and lung
cancer was found in central regions of Argentina [67], where
arsenic concentrations in water supplies were >100μg/L,
even reaching as high as 2000μg/L [68]. A correlation
between increased arsenic concentration in drinking water
and lung cancer incidence was also discovered in Northern
Chile [25]. In this area, lung cancer mortality increased
ten years after the initiation of high-level exposure (arsenic
concentration >90μg/L in 1958) [10].
Chronic exposures to water contaminated with low con-
centrations of arsenic do not, however, show the same
strong associations with increased cancer incidence and
mortality. For example, a study carried out in Denmark [69]
did not ﬁnd any signiﬁcant association between exposure
to low concentrations of arsenic in drinking water (0.05–
25.3μg/L) and risk of melanoma or lung cancer, among
other types of neoplasias. Similarly, another study conducted
in Belgium did not ﬁnd a signiﬁcant correlation between
exposure to drinking water containing relatively low arsenic
concentrations (20–50μg/L) and lung cancer mortality [70].
Genetic factors are thought to modulate susceptibili-
ty to arsenic-induced lung cancer. Carriers of CYP1A1∗
2A/GSTM1 homozygous deletion genotype show increased
odds ratios for lung cancer, especially among smokers [71,
72]. In addition, our group has recently proposed that
genomic aberrations in arsenic induced lung cancers exhibit
distinct molecular characteristics. Using a whole genome
tiling-path comparative genomic hybridization (CGH) array
platform (described in [73]), we analyzed DNA copy-
number alterations (CNAs) among lung SqCC cases from a
Northern Chilean population chronically exposed to inor-
ganic arsenic in drinking water (Figure 1)[ 74]. We identiﬁed
unique patterns of chromosomal disruption and gene dosage
related to SqCC from never smokers in Northern Chile,
which did not correlate with normal DNA copy-number
variations (Figure 1). This has led to the growing hypothesis
that lung SqCC in arsenic-exposed individuals could repre-
sent a molecularly distinct form of this disease [74].
3. CarcinogenicMechanismsof
ArsenicExposure
3.1. Arsenic Biotransformation as a Toxicity Activation Mech-
anism. Arsenic metabolism implicates a series of reduction
and oxidation reactions. Pentavalent arsenical species are
reduced to trivalent species, and oxidative methylation
occurs to yield methylated tri- and pentavalent metabolites
[75]. However, more than a detoxiﬁcation mechanism, it
has been proposed that methylation can activate the toxic
and carcinogenic potential of arsenic, since it has been
demonstrated that mono/dimethylated arsenical species
(both tri/pentavalent) can aﬀect gene transcription, and are
more potent enzyme inhibitors and cytotoxins than non-
methylated species [76, 77]. Moreover, since the arsenic bio-
transformation pathway uses S-adenosylmethionine (SAM)
as a methyl group donor, arsenic can also interfere with
a number of cellular processes that require methyl groups,
leading to the idea that alteration of epigenetic mechanisms
can also participate in arsenic-induced carcinogenesis [78].
A variety of these arsenic associated toxic events have been
elucidated in cell line and animal models (Table 1).
AfterreductionofAsV toAsIII bypurinenucleosidephos-
phorylase, AsIII is methylated via a AsIII-methyltransferase,
using SAM as a methyl group donor [79], producing mono
and dimethylated trivalent species, such as monomethylar-
sonous acid (MMAIII), dimethylarsinous acid (DMAIII), and
equivalent pentavalent species (monomethylarsonic acid or
MMAV, and dimethylarsinic acid or DMAV. Interestingly,
there is little evidence of methylated arsenic metabolites
in skin, and in vitro studies have demonstrated that ker-
atinocytes display very slow rates of arsenic methylation, and
only mono-methylated species are produced [45, 80]. It has
been proposed that AsIII could be one of the responsible
agents in arsenic related skin carcinogenicity, since it acts as a
cocarcinogenic to mouse skin [81]. Additionally, individuals
with arsenic-related skin lesions or skin cancer exhibit
lower levels of dimethylated species in urine (in contrast to
monomethylated species) [82–85], indicating that a lower4 Journal of Toxicology
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Figure 1: Genome-wide identiﬁcation of arsenic-related and smoking independent DNA copy number alterations in lung squamous cell
carcinoma(SqCC).GenomiccopynumberproﬁlesforlungSqCCbiopsies(n = 52)wereobtainedusingwholegenomeaCGH.SqCCtumors
from smokers (n = 42), comprised (n = 30) samples from North American with no known arsenic exposure, and (n = 12) samples from
Northern Chile from individuals chronically exposed to arsenic. SqCC tumors from never smokers (n = 10) were from chronically arsenic-
exposedindividualsfromNorthernChile.(a)Frequency plotofarsenic-related andsmokingindependentcopynumberdiﬀerences inSqCC.
The frequency of DNA gain/loss for each probe was calculated and plotted for each group, where smokers (dark green) and never smokers
(red). Regions exhibiting similar alteration in both groups are denoted in yellow. The magnitude of green and red bars represents percent
alteration for each probe per group (0–100%, with blue vertical lines representing 50% frequency). DNA gains and losses are represented
to the right and left of each chromosome, respectively. Analysis was restricted to autosomes, with any diﬀerences based on sex subtracted
from further analysis. A high frequency of copy number alteration, previously undescribed for SqCC were evident in arsenic exposed tumors
from never smokers, particularly for chromosome 3q. (b) Detail of DNA losses at 10q11.23 speciﬁc to never smokers are highlighted in a
light-blue rectangle. PARG, previously shown to mediate cell death in response to genotoxic stimuli (PMID: 19571039), is indicated in red.
(c) Recurrent DNA gain found in never smokers at 19q13.33. This segment contains the POLD1 gene, a DNA polymerase delta complex,
involved in DNA replication and repair (red probe).Journal of Toxicology 5
Table 1: Changes in functions associated to arsenic-related carcinogenicity.
Type of alteration Cell model/type As species Reference
Associated to oxidative stress
DNA strand break Human fetal lung ﬁbroblast (2BS
cells) AsIII [121]
DNA strand break Human alveolar epithelial type II
(L-132) cells DMAV [122]
Single-strand DNA breaks, DNA-protein adducts, sister
chromatid exchanges Human ﬁbroblast cell lines AsIII [123]
Formation of apurinic/apyrimidinic sites Human alveolar epithelial cell
line (L-132) DMA [124]
Induction of 8-OHdG Human breast cancer MCF-7
adenocarcinoma epithelial cells AsIII [125]
Increases 8-oxo-G levels through (CH3)2AsOO DMAV [126, 127]
Presence markers for oxidative stress were detected,
including 8-oxodG Mouse bronchiolar Clara cells DMAV [128]
Double-strand DNA breaks Mammalian cells [96]
Epigenetic changes in DNA methylation/histones
modiﬁcation/miRNA expression
Alteration of methylation in p53 promoter A549 cell line AsIII
AsV [106]
Inductor of hypermethylation of the p16INK4a and
RASSF1A CpG islands in nontumor lung tissues (including
hyperplasia and adenoma) and lung adenocarcinomas
Lungs of mice exposed during 18
months AsV [107]
Increase of dimethylated H3K9 Human BEAS-2B cell line AsIII [112]
Increased H3K9 dimethylation and decreased H3K27
tri-methylation (gene silencing), increasing H3K4
tri-methylation (gene-activating mark), increases histone
methyltransferase G9a protein levels
Human A549 cell line AsIII [112]
Changes to histone H3 acetylation, DNA promoter
methylation, and decreases expression of the DBC1,
FAM83A, ZSCAN12,a n dC1QTNF6 genes
Human nontumorogenic cell
lines [113]
Altered expression of hsa-miR-210, -22, -34a, -221, and -222 Human lymphoblastoid cells AsIII [116]
Reduction in levels of miR-200
Immortalized p53-knocked
down human bronchial epithelial
cells (HBECs)
AsIII [117]
Decrease in expression of miRNA-9, -181b, -124, and -125b Chick embryos AsIII [118]
Other changes
Ampliﬁcation of the dihydrofolate reductase gene Mouse 3T6 cells AsIII [129]
MAPK activation; phosphorylation of ATF-2 and c-Jun,
elevated IL-8 release Human BEAS 2B line AsIII [130]
Induction of p53-independent expression of GADD45
protein (a G2/M cell-cycle checkpoint protein) Human BEAS 2B line AsIII [131]
Stabilization of GADD45 alpha mRNA through nucleolin Human BEAS 2B line AsIII [132]
Mostly decreased expression for transcripts involved in
angiogenesis, lipid metabolism, oxygen transport, apoptosis,
cell cycle, and immune response
Lung of mice exposed AsIII [133]6 Journal of Toxicology
Table 1: Continued.
Type of alteration Cell model/type As species Reference
Induction of the expression of genes involved with cancer,
the cell cycle, cellular proliferation, DNA replication,
recombination and repair, lipid metabolism, cell-cell
signaling and interaction, molecular transport, and
immunological disease pathways in Ogg1−/− mice
Lungs of Ogg1−/− mutant mice
exposed DMAV [134]
Enhanced centrosome ampliﬁcation in p53-compromised
cells. Resistance to arsenite-induced G2/M cell cycle arrest
and arsenite-induced apoptosis in p53-compromised cells.
Reductions in arsenite-induced enhancement of p53, p21,
and Gadd45a expressions (at 5–10μM), Higher (200%) cell
colony formation in p53-inhibited BEAS-2B cells (5μM)
H1355 cells (human lung
adenocarcinoma cell line with
mutation in p53) Human
BEAS-2B line p53-inhibited
BEAS-2B cells
AsIII [135]
Increased expression of ER-alpha and genes related to
estrogen signaling in the fetal lung of female mice
Lung samples from gestation day
18 female fetal C3H mice AsIII [136]
Downregulation of (validated genes): Tpi1, Ldha, and Pgk1.
Upregulation of (validated genes): Cox6a2; Variable: Id1,
Gpnmb
Rat lung epithelial cell line (L2) AsIII [137]
Increased cell viability (≤0.5μM). Downregulation of APE1
and Polβ mRNA (above 1μM)
GM847-immortalized human
lung ﬁbroblast AsIII [138]
Increased plating eﬃciency (cell growth advantage),
micronuclei incidence (marker of chromosomal instability),
gene ampliﬁcation (PALA resistance), invasive capabilities;
anchorage-independent growth (oncogenic transformation);
lost of β4 integrin expression; upregulated phosphorylation
of Rb and ERK; decreased expression of p53 protein
h-TERT-immortalized human
small airway epithelial cells AsIII [139]
methylation activity could predispose individuals to arsenic-
related skin malignancies.
3.2. Arsenic-Induced Oxidative Stress. Cellular induced dam-
age derived from arsenic biotransformation leading to
carcinogenic processes have usually been described to occur
through oxidative stress by generation of toxic species,
such as reactive oxygen species (ROS) leading to genomic
aberrations. Generation of ROS has been described as
one of the earliest and most important mechanisms of
arsenic-induced carcinogenicity [86–91]. Oxidative damage
(measured as guanine oxidation) is signiﬁcantly associated
with skin tumors associated with arsenic exposure [92, 93].
It has also been shown that oxidative stress can modify gene
transcription proﬁles of human hyperkeratosis, aﬀecting
several cancer-relevant pathways, such as the Wnt/β-catenin
and calcium signaling pathways [94, 95]. Both single- and
double DNA strand breaks are characteristic of most cancer
types and have been shown to be induced by chronic arsenic
exposure, even at low concentrations [96, 97].
3.3. Epigenetic Changes. Arsenic, arsenic metabolites, and
metabolism, directly and indirectly, aﬀect normal epigenetic
transcriptional regulation at both the level of DNA methyla-
tion,histonemaintenance,andmiRNAexpression(reviewed
in [98, 99]). As previously mentioned, biotransformation
and reduction of arsenic leads to the formation of highly
toxic methylated arsenic species which act as potent cytotox-
ics and enzyme inhibitors. Since this process utilizes SAM,
the cell’s own methyl group donor, arsenic is thought to
interfere with the cell’s ability to maintain normal epigenetic
regulation via the disruption of normal DNA methylation
patterns, histone modiﬁcation, and expression of microR-
NAs (miRNAs), possibly by the depletion of cellular pools
of methyl groups (Figure 2). Epigenetic modiﬁcations do
not alter the DNA sequence itself but instead result in
chemical modiﬁcations to DNA or histone tail residues. Cells
and tissues exposed to arsenic display epigenetic aberrations
that mimic early hallmarks of cancer, providing evidence
for an epigenetic role in arsenic-mediated tumorigenesis.
Epigenetic regulation of gene expression is a highly dynamic
process that can be modulated by existing therapeutics
[100, 101] which may potentially apply to arsenic-related
malignancies.
3.3.1. DNA Methylation. In the human genome, DNA meth-
ylation occurs at the 5-carbon position of cytosine in CpG
dinucleotide sequences, resulting in 5 -methylcytosine
(5mC), often within short evolutionarily conserved regions
enriched for CpG dinucleotides, called CpG islands
[102, 103]. When located in promoter regions of genes,
CpG islands are typically unmethylated (∼90%); however,
promoters without CpG islands are frequently methylated
[104]. Therefore, the bulk of methylated DNA in the human
genome occurs in repetitive DNA sequences, where it is
thought to have an important role in silencing transposable
elements and maintaining genomic stability. The transfer
of the donor methyl group from SAM to the cytosine in a
CpG dinucleotides is catalyzed by DNA methyl transferase
(DNMT) enzymes, responsible for the de novo methylationJournal of Toxicology 7
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Figure 2:Schematicrepresentationofproposedarsenic-inducedcarcinogenicmechanisms.Arseniccanentercellsinbothtri-orpentavalent
forms (AsIII or AsV). Inside cells, AsV is converted to AsIII, with subsequent methylation to monomethylated (MMA) and dimethylated
(DMA)species.ThemethylationofinorganicarsenicconsumesbothS-adenosylmethionine(SAM)andglutathione(GSH).Cellulardamage
derivedfromarsenicbiotransformationcanoccurthroughgenerationofreactiveoxygenspecies(ROS),andthroughepigeneticmechanisms:
changes in DNA methylation patterns (by depletion of cellular pools of methyl group), histone modiﬁcation, and altered expression of
microRNAs (miRNAs).
throughout development (DNMT3a, DNMT3b, and
DNMT3L) and maintenance of methylation patterns in so-
matic tissue (DNMT1). Aberrant DNA methylation is impli-
cated in a vast spectrum of diseases and disorders and is
one of the earliest and most frequent aberrations in cancer.
DNA hypomethylation is associated with genomic instability
and the reexpression of parasitic DNA, in addition to
activation of genes normally silenced by methylation in a
tissue-speciﬁc manner. Conversely, aberrant DNA promoter
hypermethylation is strongly linked to transcriptional gene
silencing, particularly for tumor suppressor genes (TSGs)
and cancer.
DNA methylation patterns observed in human cancers
resemble those of arsenic-related premalignant and malig-
nant cells and tissues. For example, the DNA methylation
patterns of several well-known cancer genes have been
studied in the context of, and found to correlate with, arsenic
exposure in in vitro cell models and in populations exposed
to arsenic. The activation of proliferative genes in rat liver
epithelial cell lines which undergo malignant transformation
following chronic, low-level arsenic exposure is associated
with aberrant DNA hypomethylation [105]. Exposure to
AsIII and AsV in the lung cancer cell line (A549), resulted
in promoter hypermethylation and subsequent transcrip-
tional silencing of p53 [106]. Mice, chronically exposed
to AsV through drinking water, acquire frequent promoter
hypermethylation of the tumor suppressors p16INK4A and
RASSF1A in lung tumor tissues [107]. A study analyz-
ing 351 cases of bladder cancer cases found that arsenic
exposure was associated with promoter methylation of
RASSF1A and PRSS3 [108]. Intriguingly, in one study, indi-
viduals with no cancer, but who were exposed to high arsenic
concentrations (>251μg/L), had a signiﬁcant degree of DNA
hypermethylation in promoter regions of p53 and p16INK4A
compared to nonexposed controls [109], suggesting that
arsenic related-hypermethylation events may be some of the
earliest causal tumorigenic events. Collectively, these and
other ﬁndings (see [98, 99]) support the notion that arsenic-
induced changes to DNA methylation play a role in tumor
formation.
3.3.2. Histone Modiﬁcation. Histones proteins enable con-
densation of double-stranded supercoiled eukaryotic DNA
into nucleosomes, which are made up of two copies each
of H2A, H2B, H3, and H4 proteins. The N-terminal tails of
histonesareaccessibletomodifyingenzymes,whichfunction
in catalyzing posttranslational modiﬁcations to the amino
acid residues residing within the histone tail, including
acetylation, methylation, ubiquitination, sumoylation, and
phosphorylationamongstothers[110,111].Speciﬁcpatterns
of these modiﬁcations, commonly referred to as the “histone
code”,correlatewithtranscriptionalstatesofassociatedgenes
as well as to disease phenotypes. Working in conjunction
with transcriptional coactivators or repressors, histone mod-
ifying enzymes catalyze the addition or removal of these
modiﬁcations to generally induce or maintain an (1) open
euchromatic state, through the addition of acetyl groups (via
histone acetyltransferases) or (2) a closed or heterchromatic
state, through the addition of methyl groups (via histone
methyltransferases) or removal of acetyl groups (via histone
deacetylases) on speciﬁc histone residues. Therefore, tran-
scriptional activity of associated genes correlates with the
formation of euchromatin or heterochromatin.8 Journal of Toxicology
Arsenic metabolites have been shown to modulate nor-
mal histone patterns. AsIII has also been shown to modify
methylation patterns on H3K4, H3K9, and H3K27 [112].
A549 cells exposed to 2.5–5μMo fA s III exhibited an increase
in H3K9 dimethylation and a decrease in H3K27 trimethy-
lation, both of which are associated with heterochromatin
(gene silencing), and a decrease in H3K4 trimethylation
which is associated with euchromatin formation (an activa-
tion mark). When the normal bronchial epithelial cell line
(BEAS-2B) was exposed to 1-2μMo fA s III, an increase in
dimethylation of H3K9 was observed.
Arsenic compounds were also shown to induce malig-
nant transformation of human nontumorigenic cell lines
through changes to histone H3 acetylation, DNA pro-
moter methylation, and decreases expression of the DBC1,
FAM83A, ZSCAN12,a n dC1QTNF6 genes [113]. For each
of these underexpressed genes, DNA methylation inversely
correlated with the histone acetylation levels for their re-
spective promoter regions, leading authors to conclude that
changes in histone H3 acetylation occur during arsenic-
induced malignant transformation.
3.3.3. MicroRNAs. miRNAs are small, noncoding RNA spe-
ciesthatorchestratetheexpressionofgenesinvolvedinmany
key aspects of cell biology by degradation and translational
inhibition of their target mRNAs (reviewed in [114]). In
humans, more than 1400 miRNAs have been identiﬁed to
date (miRBase data base; Release 17, April 2011). miRNAs
inhibit gene expression by binding to the 3 -untranslated
region of mRNAs through imperfect base pairing; conse-
quently, a single miRNA can negatively regulate the expres-
sion of multiple and sometimes upwards of hundreds target
genes. As a result, miRNAs deregulations are implicated in
diverse human pathologies, including cancer (reviewed in
[115]).
An increasing number of studies show that arsenic
exposure can alter miRNA expression levels in vitro and in
vivo. Human lymphoblastoid cells exposed to sodium AsIII
over six days showed altered expression of ﬁve miRNAs
(hsa-miR-210, -22, -34a, -221, and -222) [116]. The authors
hypothesizedthatthesealterationscouldbeaconsequenceof
changes in methylation patterns, since the same alterations
were observed when cells were grown under folate-deﬁcient
conditions, which can lead to reduced levels of SAM. Fur-
thermore, overexpression of hsa-miR-222 was conﬁrmed in
human peripheral blood-derived cells from individuals with
insuﬃcient dietary folate. The induced changes in miRNA
expression could be reversed by the restoration of folate,
suggesting that continuous exposure to agents like arsenic
may be necessary to permanently alter the expression of
miRNAs.
Chronic exposure to AsIII has also been shown to induce
malignant transformation and epithelial-to-mesenchymal
transition (EMT), in concert with reduction in levels of miR-
200 family members in immortalized p53-knocked down-
human bronchial epithelial cells (HBECs) but not in p53-
intact HBECs [117]. Interestingly, stable expression of miR-
200b alone was capable of entirely reversing and preventing
AsIII-induced EMT and malignant transformation. Arsenic
exposure depleted the miR-200s through the induction
of EMT-inducing transcription factors zinc-ﬁnger E-box-
binding homeobox factor 1 (ZEB1) and ZEB2 and increased
methylation of miR-200 promoters.
A recent study examining the global expression of
miRNAsandmRNAsofchickembryosafterarsenicexposure
revealed a dramatic decrease in expression of miRNA-9,
-181b, -124, and -125b [118]. NRP1—a transmembrane
receptor involved in angiogenesis—which is upregulated at
the mRNA level in arsenic-treated chick embryos was found
to be a target gene of miR-9 and miR-181b. Overexpression
of miR-9 or miR-181b suppressed AsIII-induced NRP1
expression, cell migration and tube formation, supporting
involvement of these miRNA species in AsIII-induced angio-
genesis via NRP1 gene activation.
Despiteitscarcinogenicpotential,AsIII hasalsobeenused
as a treatment option for APL, which is frequently associated
with a gene fusion involving the retinoic acid receptor alpha
(RARA) and the promyelocytic leukemia protein (PML)
gene [119]. Saumet et al. have shown that PML-RARA is
able to transcriptionally repress several miRNAs associated
with critical pathways linked to leukemogenesis, such as
HOX proteins and cell adhesion molecules [120]. Expression
of these miRNAs was restored by retinoic acid and AsIII,
suggesting that, in APL, these agents may function to inhibit
cell growth, at least in part by impacting miRNA expression.
4. Conclusion
Arsenic contamination of drinking water remains a serious
public health problem, aﬀecting hundreds of millions indi-
viduals worldwide. The more severe eﬀects, such as cancer,
are evident up to several decades after exposure has ceased.
Although mitigation measures have been taken, the natural
origin of this contamination keeps this problem an active
preoccupation that requires strategies to monitor arsenic
concentrations in drinking water and to deﬁne markers
associated with early health eﬀects.
Overall, reviewed literature indicates that arsenic expo-
sure exerts deleterious health eﬀects primarily through the
induction of oxidative stress, alterations to DNA methyla-
tion, histone modiﬁcation, and miRNA expression. Under-
standing these events in the context of arsenic toxicity may
provide powerful biomarkers for arsenic-induced carcino-
genicity and elucidation of early steps in arsenic-induced
malignancies that may be reversed by targeted therapies or
preventative chemotherapeutics. Larger, carefully designed
epidemiologic studies will be required to more compre-
hensively examine the presence and consequence of these
alterations in populations aﬀected by arsenic contamination.
Since synergistic cocarcinogenicity, especially in skin and
lung cancer, occurs in arsenic-exposed individuals, consid-
erations of other environmental agents should be taken into
account in these studies. Elucidation of the mechanisms
underlying the initiation and promotion of carcinogenesis
related to arsenic’s biotransformation processes and metabo-
lites is of foremost importance to the development of early
detection and treatment regimes for aﬀected individuals.Journal of Toxicology 9
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